Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katja Deterding

Showing results (61-70 of 98) with videos related to

Pageof 10
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|June 9, 2026
Acute HEV Infection Is a Relevant Cause of Decompensation and ACLF in Patients With Liver CirrhosisKatja Dinkelborg, Christian Niehaus, Birgit Bremer, et al.
Hepatology (Baltimore, Md.)|October 23, 2016
Antiviral treatment and liver-related complications in hepatitis deltaAnika Wranke, Beatriz Calle Serrano, Benjamin Heidrich, et al.
Antiviral Research|July 20, 2011
Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter studySi-Nafa Si-Ahmed, Pierre Pradat, Roeland Zoutendijk, et al.
Hepatology (Baltimore, Md.)|December 19, 2024
Enhancing HBV-specific T cell responses through a combination of epigenetic modulation and immune checkpoint inhibitionMelanie Urbanek-Quaing, Yin-Han Chou, Manoj Kumar Gupta, et al.
Virus Evolution|March 4, 2022
Intra-host analysis of hepaciviral glycoprotein evolution reveals signatures associated with viral persistence and clearanceAndré Gömer, Richard J P Brown, Stephanie Pfaender, et al.
European Journal of Immunology|November 29, 2021
Imprint of unconventional T-cell response in acute hepatitis C persists despite successful early antiviral treatmentYanqin Du, Tanvi Khera, Benedikt Strunz, et al.
Journal of Hepatology|May 21, 2008
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infectionAndrej Potthoff, Heiner Wedemeyer, Wulf O Boecher, et al.
The Journal of Infectious Diseases|January 31, 2021
Long-Lasting Imprint in the Soluble Inflammatory Milieu Despite Early Treatment of Acute Symptomatic Hepatitis CTanvi Khera, Yanqin Du, Daniel Todt, et al.
Clinical and Molecular Hepatology|June 4, 2025
Distinct inflammatory imprint in non-cirrhotic and cirrhotic patients before and after direct-acting antiviral therapyMoana Witte, Carlos Oltmanns, Jan Tauwaldt, et al.
Zeitschrift Fur Gastroenterologie|September 18, 2020
Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R)Johannes Vermehren, Yvonne Serfert, Markus Cornberg, et al.
Pageof 10

Showing results (61-70 of 98) with videos related to

Sort By:
Pageof 10
Liver International : Official Journal of the International Association for the Study of the Liver|June 9, 2026
Acute HEV Infection Is a Relevant Cause of Decompensation and ACLF in Patients With Liver CirrhosisKatja Dinkelborg, Christian Niehaus, Birgit Bremer, et al.
Hepatology (Baltimore, Md.)|October 23, 2016
Antiviral treatment and liver-related complications in hepatitis deltaAnika Wranke, Beatriz Calle Serrano, Benjamin Heidrich, et al.
Antiviral Research|July 20, 2011
Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter studySi-Nafa Si-Ahmed, Pierre Pradat, Roeland Zoutendijk, et al.
Hepatology (Baltimore, Md.)|December 19, 2024
Enhancing HBV-specific T cell responses through a combination of epigenetic modulation and immune checkpoint inhibitionMelanie Urbanek-Quaing, Yin-Han Chou, Manoj Kumar Gupta, et al.
Virus Evolution|March 4, 2022
Intra-host analysis of hepaciviral glycoprotein evolution reveals signatures associated with viral persistence and clearanceAndré Gömer, Richard J P Brown, Stephanie Pfaender, et al.
European Journal of Immunology|November 29, 2021
Imprint of unconventional T-cell response in acute hepatitis C persists despite successful early antiviral treatmentYanqin Du, Tanvi Khera, Benedikt Strunz, et al.
Journal of Hepatology|May 21, 2008
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infectionAndrej Potthoff, Heiner Wedemeyer, Wulf O Boecher, et al.
The Journal of Infectious Diseases|January 31, 2021
Long-Lasting Imprint in the Soluble Inflammatory Milieu Despite Early Treatment of Acute Symptomatic Hepatitis CTanvi Khera, Yanqin Du, Daniel Todt, et al.
Clinical and Molecular Hepatology|June 4, 2025
Distinct inflammatory imprint in non-cirrhotic and cirrhotic patients before and after direct-acting antiviral therapyMoana Witte, Carlos Oltmanns, Jan Tauwaldt, et al.
Zeitschrift Fur Gastroenterologie|September 18, 2020
Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R)Johannes Vermehren, Yvonne Serfert, Markus Cornberg, et al.
Pageof 10